Human Pathology
Volume 41, Issue 1 , Pages 103-106 , January 2010

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer

  • Sejal S. Shah, MD

      Affiliations

    • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    • ,
  • Rhett P. Ketterling, MD

      Affiliations

    • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    • ,
  • Matthew P. Goetz, MD

      Affiliations

    • Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    • ,
  • James N. Ingle, MD

      Affiliations

    • Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    • ,
  • Carol A. Reynolds, MD

      Affiliations

    • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    • ,
  • Edith A. Perez, MD

      Affiliations

    • Department of Hematology-Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    • ,
  • Beiyun Chen, MD, PhD

      Affiliations

    • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    • Corresponding Author InformationCorresponding author. Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA.

Received 28 April 2009 ,Revised 2 July 2009 ,Accepted 9 July 2009.

References 

  1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  3. Offersen BV, Alsner J, Ege Olsen K, et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol. 2008;47:618–632
  4. Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991;63:447–450
  5. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998;16:1340–1349
  6. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991;63:434–438
  7. Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg. 2000;135:1469–1474
  8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  9. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  10. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  11. Hayes DF, Picard MH. Heart of darkness: the downside of trastuzumab. J Clin Oncol. 2006;24:4056–4058
  12. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18
  13. Lal P, Salazar PA, Hudis CA, Ladanyi M, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004;121:631–636
  14. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000;53:374–381
  15. McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol. 2002;117:935–943
  16. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17:1974–1982
  17. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866–873
  18. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;19:354–363
  19. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol. 1997;10:720–727
  20. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63–72
  21. Hoang MP, Sahin AA, Ordòñez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113:852–859
  22. Lal P, Salazar PA, Ladanyi M, Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn. 2003;5:155–159
  23. Varshney D, Zhou YY, Geller SA, Alsabeh R. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004;121:70–77
  24. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol. 2005;124:273–281
  25. Striebel JM, Bhargava R, Horbinski C, Surti U, Dabbs DJ. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Am J Clin Pathol. 2008;129:383–390
  26. Dastane AM, Alsabeh R, Bose S. Effect of ASCO/CAP Recommended Guideline for Positive Her2/neu Stain on FISH Concordance—an evidence based study. Mod Pathol. 2008;28A:21
  27. Gilmore HL, Collins LC, Connolly JL, Schnitt SJ. Impact of the New American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines on the Determination of Breast Cancer HER2 Status. Mod Pathol. 2008;32A:21
  28. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358:1409–1411
  29. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol. 2007;25(18S):512

PII: S0046-8177(09)00251-2

doi: 10.1016/j.humpath.2009.07.001

Human Pathology
Volume 41, Issue 1 , Pages 103-106 , January 2010

Article Tools